Our Pricing

Understanding Mounjaro NHS Availability and Private Prescription Routes

Published on: June 03, 2026

Weighing up mounjaro nhs vs private uk options can feel overwhelming when you're ready to start treatment. While NHS access to Mounjaro (tirzepatide) remains highly restricted with strict eligibility criteria and lengthy waiting lists, private prescription routes offer immediate assessment and transparent pricing from £124.99 at Cured Pharmacy, with genuine UK-licensed medication dispensed by our GPhC-registered team.

Can You Get Mounjaro on the NHS?

Mounjaro is licensed by the MHRA for weight management in the UK, but NHS availability is extremely limited. NICE guidance currently restricts NHS-funded tirzepatide to patients meeting very specific criteria: a BMI of 35 or above with at least one weight-related comorbidity, or a BMI of 30 or above in certain circumstances, and only after documented failure of intensive lifestyle interventions through specialist weight management services [1].

Even if you meet these criteria, NHS Mounjaro is typically only available through specialist hospital-based obesity clinics rather than GP practices. Waiting lists for these services can extend beyond 12 months in many UK regions, and not all NHS trusts have commissioned tirzepatide due to budget constraints [2].

The reality is that most UK patients seeking Mounjaro will need to access it privately. This allows immediate clinical assessment without waiting lists, though all prescriptions still require approval from a UK-registered prescriber based on your individual medical history and suitability.

Mounjaro Private Prescription: What to Expect

Private access to Mounjaro follows the same clinical safety standards as NHS prescribing, but without the restrictive eligibility criteria or waiting times. At Cured Pharmacy, our UK-registered prescribers assess each patient individually, considering your BMI, medical history, previous weight loss attempts, and any contraindications.

The private prescription process begins with a comprehensive online consultation that takes under three minutes to complete. Our clinical team reviews your assessment within hours, and if Mounjaro is deemed suitable and safe for you, your prescription is issued and dispensed from our GPhC-registered pharmacy (registration number 9012511). All medication is genuine UK-licensed Mounjaro KwikPens, delivered in 100% discreet packaging.

Private prescription eligibility is generally broader than NHS criteria, though clinical safety remains paramount. Most prescribers will consider Mounjaro for patients with a BMI of 30 or above, or 27 or above with weight-related health conditions, subject to individual assessment and prescriber approval [3].

Ongoing Private Care and Monitoring

Private Mounjaro treatment isn't just about the initial prescription. Reputable UK pharmacies like Cured Pharmacy provide ongoing clinical support, with regular check-ins to monitor your progress, manage any side effects, and adjust dosing as needed. Your treatment plan typically involves gradual dose escalation over several months, following the licensed titration schedule to optimise efficacy while minimising gastrointestinal side effects [4].

Mounjaro NHS vs Private: Cost Comparison

The most obvious difference between NHS and private routes is cost. NHS prescriptions carry the standard prescription charge (currently £135.00 per item in England, free in Scotland, Wales, and Northern Ireland, or free with a valid exemption certificate). However, accessing Mounjaro through the NHS requires meeting the strict eligibility criteria and navigating lengthy specialist referral pathways.

Private Mounjaro prescriptions at Cured Pharmacy start from £124.99 with transparent upfront pricing shown before you begin your consultation. This includes the medication, clinical assessment, prescription, and discreet home delivery. Unlike some providers, we guarantee the lowest prices in the UK and never add hidden fees at checkout.

When comparing costs, consider the full picture: private access eliminates waiting times that could extend beyond a year on the NHS, provides immediate clinical support, and allows you to start treatment when you're ready rather than when a specialist appointment becomes available. For many UK patients, the investment in private prescription represents better value than delaying treatment indefinitely.

How Mounjaro Compares to Other Weight Loss Treatments

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed for weight management in the UK. This dual mechanism sets it apart from single-pathway GLP-1 agonists like semaglutide (Wegovy) and liraglutide (Saxenda). By activating both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, tirzepatide produces more pronounced effects on appetite regulation, glucose metabolism, and weight reduction [5].

Clinical trial data demonstrates Mounjaro's superior efficacy. In the SURMOUNT-1 trial, patients taking the 15mg dose achieved an average 22.5% body weight reduction over 72 weeks, compared to approximately 15% with semaglutide 2.4mg in the STEP trials [5][6]. Both medications require weekly subcutaneous injection and follow similar titration schedules, but the magnitude of weight loss observed with tirzepatide has made it a preferred option for many UK prescribers and patients.

Alternative treatments like Saxenda require daily injections rather than weekly, while oral options like Orlistat work through fat absorption blocking rather than appetite regulation. Your UK prescriber will recommend the most appropriate treatment based on your individual circumstances, preferences, and clinical profile.

Choosing Between Mounjaro and Wegovy

Both Mounjaro and Wegovy are highly effective injectable weight loss medications licensed in the UK, but they suit different patients. Wegovy may be more appropriate if you're seeking a well-established GLP-1 treatment with extensive long-term safety data, while Mounjaro offers potentially greater weight loss results based on head-to-head trial comparisons. At Cured Pharmacy, Wegovy is available from £124.99 making it a more accessible option for some patients, though individual suitability always takes precedence over cost considerations.

Mounjaro Eligibility: NHS Criteria vs Private Assessment

NHS eligibility for Mounjaro is determined by NICE guidance and local commissioning decisions. You'll typically need a BMI of 35 or above with documented weight-related comorbidities such as type 2 diabetes, hypertension, or obstructive sleep apnoea. Some NHS trusts may consider patients with a BMI of 30-34.9 if they have significant metabolic complications, but this varies by region [1].

Crucially, NHS prescribing also requires evidence of previous intensive lifestyle interventions through specialist services, including structured diet programmes, increased physical activity, and behavioural support. You'll need to demonstrate that these interventions have been unsuccessful before Mounjaro is considered, and even then, access is subject to local formulary decisions and budget availability [2].

Private prescription eligibility is assessed on an individual basis by UK-registered prescribers. While BMI thresholds still apply (typically 30 or above, or 27 or above with weight-related conditions), the requirement for prior specialist service engagement is removed. This makes private access suitable for patients who are clinically appropriate for treatment but don't meet the restrictive NHS pathway criteria or cannot access specialist obesity services in their area.

Starting Mounjaro Treatment: Private Prescription Process at Cured Pharmacy

Beginning private Mounjaro treatment at Cured Pharmacy is straightforward and clinically safe. Start by completing our free online consultation, which takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications. Our UK-registered clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews every assessment individually.

If Mounjaro is deemed appropriate and safe for you, your prescription is issued and your medication is dispensed from our GPhC-registered pharmacy. We supply only genuine UK-licensed Mounjaro KwikPens, never grey-market or unlicensed imports. Your first delivery includes your starting dose (typically 2.5mg weekly), full injection instructions, and guidance on the titration schedule you'll follow over subsequent months [4].

Ongoing support is included in your treatment. Our clinical team monitors your progress, manages any side effects, and adjusts your prescription as you progress through the dose escalation phases. You'll have direct access to UK-registered pharmacists and prescribers throughout your treatment journey, ensuring safe and effective weight management with Mounjaro.

What Happens After Your Assessment

Once approved, your Mounjaro prescription is processed immediately and dispatched in discreet, unmarked packaging. Delivery typically arrives within 1-3 working days to any UK address. You'll receive clear instructions on injection technique, storage requirements, and what to expect during your first weeks of treatment. If your assessment identifies any clinical concerns or contraindications, our prescribers will recommend alternative treatments or advise you to consult your GP for further evaluation before starting Mounjaro.

Scientific References

1. National Institute for Health and Care Excellence. (2023). Tirzepatide for managing overweight and obesity [TA888]. NICE. https://www.nice.org.uk/guidance/ta888 [accessed 13 August 2026]
2. NHS England. (2023). National Specialised Commissioning: Clinical Commissioning Policy: Treatment of Severe and Complex Obesity. NHS England. [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 13 August 2026]
4. Eli Lilly and Company. (2023). Mounjaro (tirzepatide) Prescribing Information. Eli Lilly. [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.